Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins

By D. Kuhn, T. George, J. Chandra, P. Mukherjee, M. Ghannoum. Antimicrobial Agents and Chemotherapy, 2002

813 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/46118f2a9d00954997163b0cb84d7102990947c2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. S. Saville
2. J. López-Ribot
3. G. Ramage
4. E. Kojic
5. J. Nosanchuk
6. R. Darouiche
7. G. Donelli
8. D. Trofa

In Molecular Biology

1. S. Saville
2. J. López-Ribot
3. G. Ramage
4. Derek P. Thomas
5. R. Darouiche
6. G. Donelli
7. E. Kojic

Citations in the corpus

• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, neutral): “activity against Candida biofilms [356].”
• A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing (2008, background): “However, newer antifungal agents, such as the echinocandins and liposomal formulations of amphotericin B, display increased efficacy against fungal biofilm”
• Candida parapsilosis, an Emerging Fungal Pathogen (2008, background): “parapsilosis usually require removal for fungal clearance, although some single-case studies report successful treatment of biofilm-associated infections with antifungal therapy alone (146, 176, 190, 228).”
• Candida Biofilms: an Update (2005, background): “However, newer antifungal agents, such as the echinocandins and liposomal formulations of amphotericin B, show increased activity against Candida biofilms (4, 5, 54, 77).”
• Candida Infections of Medical Devices (2004, background): “parapsilosis biofilms (57); however, caspofungin has been shown to be effective against C.”
• Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. (2013, background): “Although C. albicans is the most commonly isolated fungal species, other species are being isolated with increasing frequency (Kuhn et al., 2002).”
• Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action (2017, background): “biofilm but also investigates biofilm drug susceptibility keeping the biofilm structure undisrupted.(101)”
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “The echinocandins and lipid formulations of amphotericin B can impact fungal growth in biofilms better than amphotericin B and azoles [119].”
• Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America (2009, background): “Echinocandins [194], lipid formulations of amphotericin B [194, 195], or ethanol-based lock solutions [196, 197] eradicate biofilm-containing Candida in vitro, but catheter retention in combination with antifungal lock therapy is still investigational at the present time.”